Biological
Tecemotide clinical trials
Also written EMD531444.
- studies test it
- 12
- open now
- 0
- in phase 3
- 4
- first study started
- 2000
How studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
12 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Merck KGaA, Darmstadt, Germany (6) · EMD Serono (4) · ECOG-ACRIN Cancer Research Group (1) · Prof. Dr. Carl Schimanski (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tecemotide is read from its arms, and is right about nine times in ten.
Testing it · 12
- BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by SurgeryCompletedPhase 2ECOG-ACRIN Cancer Research GroupNCT00828009Written as Tecemotide
- Tecemotide (L-BLP25) in Prostate CancerCompletedPhase 2EMD SeronoNCT01496131Written as Tecemotide (L-BLP25)
- L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic MetastasesCompletedPhase 2Prof. Dr. Carl SchimanskiNCT01462513Written as L-BLP25
- Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung CancerTerminatedPhase 3EMD SeronoNCT02049151Written as Tecemotide
- Tecemotide (L-BLP25) in Rectal CancerCompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT01507103Written as Tecemotide (L-BLP25)
- Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian PopulationTerminatedPhase 3Merck KGaA, Darmstadt, GermanyNCT01015443Written as Tecemotide
- Common Safety Follow-up Trial of Tecemotide (L-BLP25)TerminatedNot applicableMerck KGaA, Darmstadt, GermanyNCT01423760Written as Tecemotide
- Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)CompletedPhase 3EMD SeronoNCT00409188Written as Tecemotide (L-BLP25)
- Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)CompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT00157209Written as Tecemotide (L-BLP25)
- Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary ChemoradiotherapyCompletedPhase 1/2Merck KGaA, Darmstadt, GermanyNCT00960115Written as Tecemotide (L-BLP25)
- Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III DiseaseCompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT00157196Written as Tecemotide (L-BLP25)
- STRIDE - STimulating Immune Response In aDvanced brEast CancerTerminatedPhase 3EMD SeronoNCT00925548Written as Tecemotide (L-BLP25) and Hormonal Treatment
Given in every arm · 1 — tecemotide is usual care beside what is tested
Codes
What other systems call tecemotide · ClinicalTrials.gg INT005054
- UNII (FDA) Q7Y026G2CXTECEMOTIDEOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Q7Y026G2CX | TECEMOTIDE | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.